Table 5

Subgroup analysis: identification and management of abnormal CRFs

Group A (RA)

Rh

Group A (RA)

PCP

Group B (DM)

Group C (GP)

P, Group A (Rh versus PCP)

P, all three (PCP)

P, A versus C (PCP)


Smoking

Abnl (n)

36

36

48

56

ID

6 (17%)

29 (81%)

40 (83%)

49 (88%)

< 0.0001

0.7

0.4

MA

5 (14%)

20 (56%)

25 (52%)

34 (61%)

0.0004

0.7

0.7


Weight

Abnl (n)

160

160

222

162

ID

41 (26%)

72 (45%)

176 (79%)

92 (57%)

0.0004

< 0.0001

0.04

MA

13 (8%)

49 (31%)

151 (68%)

74 (46%)

< 0.0001

< 0.0001

0.006


SBP

Abnl (n)

132

132

199

150

ID

119 (90%)

131 (99%)

198 (99.9%)

149 (99%)

0.001

0.9

1

MA

12 (9%)

44 (33%)

146 (73%)

64 (43%)

< 0.0001

< 0.0001

0.1


DBP

Abnl (n)

45

45

45

52

ID

43 (96%)

45

45

52

0.5

1

1

MA

8 (18%)

18 (40%)

35 (78%)

30 (58%)

0.04

< 0.001

0.1


HDL

Abnl (n)

26

26

75

33

ID

2 (8%)

11 (42%)

56 (75%)

22 (67%)

0.009

< 0.01

0.07

MA

1 (4%)

4 (15%)

38 (51%)

13 (39%)

0.3

< 0.0001

0.08


LDL

Abnl (n)

39

39

102

33

ID

1 (3%)

23 (59%)

85 (83%)

26 (79%)

< 0.0001

0.009

0.08

MA

1 (3%)

16 (41%)

76 (75%)

21 (64%)

< 0.0001

0.0009

0.06


TG

Abnl (n)

53

53

130

54

ID

6 (11%)

31 (59%)

110 (85%)

36 (67%)

< 0.0001

< 0.0003

0.4

MA

3 (6%)

17 (32%)

86 (66%)

20 (37%)

0.0009

< 0.0001

0.7


FBG

Abnl (n)

26

26

141

36

ID

0

12 (46%)

135 (96%)

16 (44%)

< 0.0001

< 0.0001

1

MA

0

2 (8%)

132 (94%)

8 (22%)

0.5

< 0.0001

0.2


All patients included in this subgroup analysis had an abnormal value for a given risk factor. Percentages are calculated as the number of patients with an identified or managed risk factor divided by the number of patients with abnormal values for the given risk factor. Abnl, abnormal; DBP, diastolic blood pressure; DM, diabetes mellitus; FBG, fasting blood glucose; GP, general population; HDL, high-density lipoprotein; ID, identified; LDL, low-density lipoprotein; MA, managed; RA, rheumatoid arthritis; Rh, rheumatologist; SBP, systolic blood pressure; TG, triglyceride.

Desai et al. Arthritis Research & Therapy 2012 14:R270   doi:10.1186/ar4118

Open Data